BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE INHIBITORS
The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-IR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-IR kinase inhibitor, comprising assessi...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | BUCK, ELIZABETH, A |
| description | The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-IR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-IR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by IGF-IR kinase inhibitors. Improved methods for treating cancer patients with IGF-IR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to IGF-IR kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by IGF-IR kinase inhibitors are also provided. pErk, HER3 and pHER are also demonstrated to be effective biomarkers for predicting sensitivity of tumor cells to IGF- IR kinase inhibitors.
L'invention concerne des procédés de diagnostic et de pronostic qui permettent de prédire l'efficacité d'un traitement par un inhibiteur de kinase IGF-1R chez un patient souffrant d'un cancer. Les procédés de l'invention permettent de prédire la sensibilité de la croissance d'une cellule tumorale à l'inhibition par un inhibiteur de kinase IGF-1R, lesquels procédés consistent à évaluer si la cellule tumorale a subi une transition épithélio-mésenchymateuse (TEM) en mesurant le niveau d'expression de biomarqueurs épithéliaux et/ou mésenchymateux, les cellules tumorales qui ont subi une transition TEM étant notablement moins sensibles à l'inhibition par les inhibiteurs de kinase IGF-1R. L'invention se rapporte à des procédés améliorés qui permettent de traiter des patients atteints de cancer par des inhibiteurs de kinase IGF-1R selon la méthodologie précitée. L'invention concerne en outre des procédés qui permettent d'identifier de nouveaux biomarqueurs prédictifs d'une réponse tumorale aux inhibiteurs de kinase IGF-1R. L'invention se rapporte aussi à des procédés d'identification d'agents destinés à renforcer la sensibilité des cellules tumorales ayant subi une transition TEM à l'inhibition par des inhibiteurs de kinase IGF-1R. Il a aussi été démontré que pErk, HER3 et pHER sont d |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2009045361A3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2009045361A3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2009045361A33</originalsourceid><addsrcrecordid>eNqNyrEKwjAUheEuDqK-wwXnQGtVcEzjbXtpzA1JtGMpEifRQn1_zOADOJ2fw7fMpopYc0NKarhI16HzYB2eSQW6IXAN0gQSShqFDhx6y8YjBAYy_qrJCE0dQuO4Dy3UUgV2okhQoU0JHRmZPJmWKkqHX2eLx_ic4-a3q2xbY1CtiNN7iPM03uMrfoaed3l-yveH8ljIsvxPfQG9STjS</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE INHIBITORS</title><source>esp@cenet</source><creator>BUCK, ELIZABETH, A</creator><creatorcontrib>BUCK, ELIZABETH, A</creatorcontrib><description>The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-IR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-IR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by IGF-IR kinase inhibitors. Improved methods for treating cancer patients with IGF-IR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to IGF-IR kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by IGF-IR kinase inhibitors are also provided. pErk, HER3 and pHER are also demonstrated to be effective biomarkers for predicting sensitivity of tumor cells to IGF- IR kinase inhibitors.
L'invention concerne des procédés de diagnostic et de pronostic qui permettent de prédire l'efficacité d'un traitement par un inhibiteur de kinase IGF-1R chez un patient souffrant d'un cancer. Les procédés de l'invention permettent de prédire la sensibilité de la croissance d'une cellule tumorale à l'inhibition par un inhibiteur de kinase IGF-1R, lesquels procédés consistent à évaluer si la cellule tumorale a subi une transition épithélio-mésenchymateuse (TEM) en mesurant le niveau d'expression de biomarqueurs épithéliaux et/ou mésenchymateux, les cellules tumorales qui ont subi une transition TEM étant notablement moins sensibles à l'inhibition par les inhibiteurs de kinase IGF-1R. L'invention se rapporte à des procédés améliorés qui permettent de traiter des patients atteints de cancer par des inhibiteurs de kinase IGF-1R selon la méthodologie précitée. L'invention concerne en outre des procédés qui permettent d'identifier de nouveaux biomarqueurs prédictifs d'une réponse tumorale aux inhibiteurs de kinase IGF-1R. L'invention se rapporte aussi à des procédés d'identification d'agents destinés à renforcer la sensibilité des cellules tumorales ayant subi une transition TEM à l'inhibition par des inhibiteurs de kinase IGF-1R. Il a aussi été démontré que pErk, HER3 et pHER sont des biomarqueurs efficaces qui permettent de prédire la sensibilité des cellules tumorales aux inhibiteurs de kinase IGF-1R.</description><language>eng ; fre</language><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; PHYSICS ; TESTING</subject><creationdate>2009</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090723&DB=EPODOC&CC=WO&NR=2009045361A3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76294</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090723&DB=EPODOC&CC=WO&NR=2009045361A3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BUCK, ELIZABETH, A</creatorcontrib><title>BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE INHIBITORS</title><description>The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-IR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-IR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by IGF-IR kinase inhibitors. Improved methods for treating cancer patients with IGF-IR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to IGF-IR kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by IGF-IR kinase inhibitors are also provided. pErk, HER3 and pHER are also demonstrated to be effective biomarkers for predicting sensitivity of tumor cells to IGF- IR kinase inhibitors.
L'invention concerne des procédés de diagnostic et de pronostic qui permettent de prédire l'efficacité d'un traitement par un inhibiteur de kinase IGF-1R chez un patient souffrant d'un cancer. Les procédés de l'invention permettent de prédire la sensibilité de la croissance d'une cellule tumorale à l'inhibition par un inhibiteur de kinase IGF-1R, lesquels procédés consistent à évaluer si la cellule tumorale a subi une transition épithélio-mésenchymateuse (TEM) en mesurant le niveau d'expression de biomarqueurs épithéliaux et/ou mésenchymateux, les cellules tumorales qui ont subi une transition TEM étant notablement moins sensibles à l'inhibition par les inhibiteurs de kinase IGF-1R. L'invention se rapporte à des procédés améliorés qui permettent de traiter des patients atteints de cancer par des inhibiteurs de kinase IGF-1R selon la méthodologie précitée. L'invention concerne en outre des procédés qui permettent d'identifier de nouveaux biomarqueurs prédictifs d'une réponse tumorale aux inhibiteurs de kinase IGF-1R. L'invention se rapporte aussi à des procédés d'identification d'agents destinés à renforcer la sensibilité des cellules tumorales ayant subi une transition TEM à l'inhibition par des inhibiteurs de kinase IGF-1R. Il a aussi été démontré que pErk, HER3 et pHER sont des biomarqueurs efficaces qui permettent de prédire la sensibilité des cellules tumorales aux inhibiteurs de kinase IGF-1R.</description><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>PHYSICS</subject><subject>TESTING</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2009</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyrEKwjAUheEuDqK-wwXnQGtVcEzjbXtpzA1JtGMpEifRQn1_zOADOJ2fw7fMpopYc0NKarhI16HzYB2eSQW6IXAN0gQSShqFDhx6y8YjBAYy_qrJCE0dQuO4Dy3UUgV2okhQoU0JHRmZPJmWKkqHX2eLx_ic4-a3q2xbY1CtiNN7iPM03uMrfoaed3l-yveH8ljIsvxPfQG9STjS</recordid><startdate>20090723</startdate><enddate>20090723</enddate><creator>BUCK, ELIZABETH, A</creator><scope>EVB</scope></search><sort><creationdate>20090723</creationdate><title>BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE INHIBITORS</title><author>BUCK, ELIZABETH, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2009045361A33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2009</creationdate><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>PHYSICS</topic><topic>TESTING</topic><toplevel>online_resources</toplevel><creatorcontrib>BUCK, ELIZABETH, A</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BUCK, ELIZABETH, A</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE INHIBITORS</title><date>2009-07-23</date><risdate>2009</risdate><abstract>The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-IR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-IR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by IGF-IR kinase inhibitors. Improved methods for treating cancer patients with IGF-IR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to IGF-IR kinase inhibitors. Furthermore, methods for the identification of agents that restore the sensitivity of tumor cells that have undergone EMT to inhibition by IGF-IR kinase inhibitors are also provided. pErk, HER3 and pHER are also demonstrated to be effective biomarkers for predicting sensitivity of tumor cells to IGF- IR kinase inhibitors.
L'invention concerne des procédés de diagnostic et de pronostic qui permettent de prédire l'efficacité d'un traitement par un inhibiteur de kinase IGF-1R chez un patient souffrant d'un cancer. Les procédés de l'invention permettent de prédire la sensibilité de la croissance d'une cellule tumorale à l'inhibition par un inhibiteur de kinase IGF-1R, lesquels procédés consistent à évaluer si la cellule tumorale a subi une transition épithélio-mésenchymateuse (TEM) en mesurant le niveau d'expression de biomarqueurs épithéliaux et/ou mésenchymateux, les cellules tumorales qui ont subi une transition TEM étant notablement moins sensibles à l'inhibition par les inhibiteurs de kinase IGF-1R. L'invention se rapporte à des procédés améliorés qui permettent de traiter des patients atteints de cancer par des inhibiteurs de kinase IGF-1R selon la méthodologie précitée. L'invention concerne en outre des procédés qui permettent d'identifier de nouveaux biomarqueurs prédictifs d'une réponse tumorale aux inhibiteurs de kinase IGF-1R. L'invention se rapporte aussi à des procédés d'identification d'agents destinés à renforcer la sensibilité des cellules tumorales ayant subi une transition TEM à l'inhibition par des inhibiteurs de kinase IGF-1R. Il a aussi été démontré que pErk, HER3 et pHER sont des biomarqueurs efficaces qui permettent de prédire la sensibilité des cellules tumorales aux inhibiteurs de kinase IGF-1R.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2009045361A3 |
| source | esp@cenet |
| subjects | INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING PHYSICS TESTING |
| title | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE INHIBITORS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T18%3A10%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BUCK,%20ELIZABETH,%20A&rft.date=2009-07-23&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2009045361A3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |